Wealth Enhancement Advisory Services LLC Purchases 47,731 Shares of Illumina, Inc. $ILMN

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Illumina, Inc. by 142.7%, acquiring 47,731 shares, which brings its total holdings to 81,168 shares valued at approximately $8.18 million.
• Illumina reported a net margin of 29.36% for the last quarter, with an earnings per share (EPS) of $1.19, exceeding analysts' expectations of $1.02.
• Analysts have varied ratings for Illumina, with a consensus rating of "Hold" and a consensus price target of $123.06, marking slight increases in price targets from several research firms.

Wealth Enhancement Advisory Services LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 142.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,168 shares of the life sciences company's stock after purchasing an additional 47,731 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.05% of Illumina worth $8,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Moors & Cabot Inc. raised its position in shares of Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after buying an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after acquiring an additional 164 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its holdings in shares of Illumina by 0.9% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company's stock worth $1,774,000 after purchasing an additional 207 shares in the last quarter. Probity Advisors Inc. increased its position in shares of Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares during the last quarter. Finally, Rise Advisors LLC raised its stake in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 224 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Evercore ISI boosted their price target on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Daiwa Capital Markets lowered Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. Daiwa America lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Canaccord Genuity Group increased their price target on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research report on Friday, August 1st. Finally, Robert W. Baird lifted their price target on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of "Hold" and a consensus price target of $123.06.

Illumina Price Performance

ILMN opened at $99.37 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $15.27 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 2.28 and a beta of 1.43. The stock's 50 day moving average price is $99.88 and its 200-day moving average price is $89.26. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's revenue was down 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.